Technical Analysis for ASRT - Assertio Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New Uptrend | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| NR7 | Range Contraction | 4.90% | |
| NR7-2 | Range Contraction | 4.90% | |
| Narrow Range Bar | Range Contraction | 4.90% | |
| Wide Bands | Range Expansion | 4.90% | |
| NR7 | Range Contraction | 5.94% | |
| Narrow Range Bar | Range Contraction | 5.94% | |
| Wide Bands | Range Expansion | 5.94% | |
| Wide Bands | Range Expansion | 5.94% |
| Alert | Time |
|---|---|
| Up 5% | 1 day ago |
| Rose Above 10 DMA | 1 day ago |
| Up 3% | 1 day ago |
| Up 2% | 1 day ago |
| Up 1% | 1 day ago |
Get this analysis on your stocks daily!
- Earnings date: 05/06/2024
Assertio Therapeutics, Inc. Description
Assertio Therapeutics, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), Cambia (diclofenac potassium for oral solution), Xartemis XR and Zipsor (diclofenac potassium). Its NUCYNTA ER (tapentadol extended release tablets) is a product for the management of pain severe enough to require daily long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults, and its NUCYNTA (tapentadol) is a product for the management of moderate to severe acute pain in adults. Its Gralise (gabapentin) is a once-daily product for the management of postherpetic neuralgia (PHN). Its Cambia (diclofenac potassium for oral solution) is a product for the acute treatment of migraine attacks.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Organ Systems Pain Organic Compounds Chemical Compounds Opioids Potassium Analgesics Acute Pain Neuropathic Pain Migraine Peripheral Neuropathy Amino Acids Diabetic Peripheral Neuropathy Treatment Of Migraine Postherpetic Neuralgia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.39 |
| 52 Week Low | 0.7324 |
| Average Volume | 1,109,901 |
| 200-Day Moving Average | 1.60 |
| 50-Day Moving Average | 0.96 |
| 20-Day Moving Average | 0.98 |
| 10-Day Moving Average | 1.06 |
| Average True Range | 0.08 |
| RSI (14) | 57.63 |
| ADX | 25.0 |
| +DI | 30.49 |
| -DI | 16.00 |
| Chandelier Exit (Long, 3 ATRs) | 1.01 |
| Chandelier Exit (Short, 3 ATRs) | 0.98 |
| Upper Bollinger Bands | 1.19 |
| Lower Bollinger Band | 0.76 |
| Percent B (%b) | 0.72 |
| BandWidth | 43.68 |
| MACD Line | 0.04 |
| MACD Signal Line | 0.03 |
| MACD Histogram | 0.0049 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.21 | ||||
| Resistance 3 (R3) | 1.20 | 1.14 | 1.18 | ||
| Resistance 2 (R2) | 1.14 | 1.11 | 1.15 | 1.17 | |
| Resistance 1 (R1) | 1.11 | 1.09 | 1.13 | 1.12 | 1.17 |
| Pivot Point | 1.05 | 1.05 | 1.06 | 1.06 | 1.05 |
| Support 1 (S1) | 1.02 | 1.02 | 1.04 | 1.03 | 0.97 |
| Support 2 (S2) | 0.96 | 1.00 | 0.97 | 0.97 | |
| Support 3 (S3) | 0.93 | 0.96 | 0.96 | ||
| Support 4 (S4) | 0.94 |
